National Healthcare Security Administration Issues 2026 National Medical Insurance Catalog Adjustment Work Plan

The recent series of documents released by China's National Healthcare Security Administration signal a fundamental transformation in how the country's basic medical insurance catalog is adjusted—evolving from a "cost-control center" to a "market ecosystem shaper." The most notable aspect is not the refinement of traditional negotiation and renewal rules but the first systematic coordination between the "Commercial Health Insurance Innovative Drug Catalog" and the basic medical insurance catalog. This move transcends a simple expansion of catalogs; it marks a key integration of the payment mechanisms within a multi-tiered healthcare security framework.

On the surface, the 2026 plan appears to be a technical update, covering the entire process from application, negotiation, renewal, to competitive bidding. However, at its core, the policy's focus is subtly shifting. Previously, pharmaceutical companies’ primary anxiety centered almost entirely on securing a spot in the national medical insurance catalog—the "single entry ticket." Negotiations were essentially zero-sum games revolving around price and market access. Now, the introduction of the Commercial Health Insurance Innovative Drug Catalog effectively establishes a parallel, market-driven second channel. This means that innovative drugs with significant clinical value but prices that may exceed the current reimbursement capacity of basic medical insurance now have the potential to be included in a multi-tiered payment system. Pharmaceutical companies must adapt their strategies accordingly, needing to study both the "basic coverage" principle of social medical insurance and the "innovation inclusiveness" of the commercial insurance catalog—the latter clearly being more aligned with real-world market demands.

The continuation of the "Competitive Bidding Rules for Non-Exclusive Drugs" and the optimization of the "Renewal Rules for Negotiated Drugs" demonstrate a delicate balancing act between encouraging innovation and controlling fund expenditures. The competitive bidding rules aim to lower prices of generic and improved new drugs through market competition, thereby creating room for innovative drugs. The more closely watched renewal rules focus on stabilizing market expectations and avoiding the "insurance-driven price-cutting" that could dampen companies' enthusiasm for sustained R&D investment. A well-designed renewal mechanism should provide drugs already in the catalog with a reasonable market return period based on their performance, rather than subjecting them to annual uncertainties of price reductions. This essentially establishes a more sustainable payment environment for genuine, original innovation.

The core signal released by this policy combination is: The medical insurance authority is transitioning from a sole payer to a rule-setter and payment system integrator within the healthcare innovation ecosystem. Basic medical insurance covers fundamentals, while the commercial insurance catalog fosters innovation—only through their linkage can the pain points of "difficulty in hospital adoption and payment" for innovative drugs be truly resolved. For example, a cutting-edge cell therapy product might struggle to enter the basic medical insurance catalog but could gain a payment pathway through the commercial insurance catalog. Patients would gain access, pharmaceutical companies would receive returns, and the pressure on the medical insurance fund would be alleviated. This opens up policy space for segmentation and differentiated development in the pharmaceutical market.

Of course, this new blueprint also presents new challenges. The sustainable development of the Commercial Health Insurance Innovative Drug Catalog depends on whether a win-win payment loop can be formed among commercial insurers, pharmaceutical companies, healthcare institutions, and patients. How should pharmaceutical companies price products for the commercial insurance catalog? How can commercial insurers design attractive products? These questions require extensive market exploration within the policy framework. Nevertheless, the direction is clear: the 2026 policy toolbox is laying a broader and more diversified track for China's pharmaceutical innovation. It no longer focuses solely on the one-dimensional goal of "price reduction" but begins to build a more resilient healthcare payment ecosystem that can accommodate both "basic coverage" and "upgraded innovation." Future competition in the pharmaceutical market will not only be a contest of product strength but also a test of the ability to understand and navigate multi-tiered payment rules.